Khondrion: Funding, Investors & Team (Sep 2026)
We are a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease. Founded by Professor Jan Smeitink, a world-leader in mitochondrial medicine, we are advancing our proprietary science through a wholly-owned clinical and preclinical small molecule pipeline of potential medicines. Our priority is to rapidly develop our pipeline to deliver transformative medicines for patients living with mitochondrial disease. Our in-house scientists are driving innovative research projects and building a portfolio of promising compounds. We have active discovery programmes underway developing new therapies, biomarkers, diagnostic applications and new read-out technologies in the field of mitochondrial diseases. Our lead pipeline asset, KH176, is a potential first-in-class oral small molecule in phase IIb clinical development to treat a range of mitochondrial diseases. It has been granted Orphan Drug Designation for MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) spectrum disorders and Leigh disease in Europe and for all inherited mitochondrial respiratory chain disorders in the US. We work in collaboration with patient organisations internationally as well as a global clinical and academic network to accelerate the discovery and development of our potential medicines for patients with mitochondrial diseases
Khondrion has raised $5.7M across 2 funding rounds on record, the most recent an undisclosed round of $5.7M announced in May 2025.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Khondrion Company Profile and Key Stats
Latest funding round on record: May 2025.
Khondrion Funding Rounds
1 of 2 rounds was announced without a disclosed amount and is excluded from the total.
Khondrion announced an undisclosed round in Nov 2024; the amount was not disclosed.
6 months later, an undisclosed round of $5.7M was announced in May 2025.
Khondrion Founders and Leadership Team
No contact details are on record for this team yet.
Khondrion Funding Compared to Other Biotechnology Startups
Khondrion's latest round of $5.7M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Khondrion in Biotechnology and Nijmegen
Companies Similar to Khondrion
The Protein Brewery is a high-tech company that specializes in developing and making animal-free- based…
Leyden Labs aims to help people live their lives to the fullest. Its platform targets commonalities of viral…
Onward is creating an Implantable Neuro-stimulation System (INS) that includes real-time motion feedback and…
Scinvivo is a medical technology company. Scinvivo is involved in bladder cancer medical needs. They provide…
Revyve produces animal-free food ingredients from microorganisms. The company's premium ingredients include…
Merus is dedicated to creating superior treatments for cancer patients and potentially finding a cure. Our…
Salvia BioElectronics is dedicated to creating new neuromodulation devices to help treat migraines. They are…
QurieGen is a biotechnology company that speeds up the process of finding and creating new drugs.
Protix Biosystems is a biometrics company that offers a range of products which enable its customers to…
QDI Systems is a startup company that engages in the development of advanced imaging devices for medical…
BIMINI Biotech, a startup established in 2019 in Leiden, The Netherlands, focuses on creating groundbreaking…
Citryll is a private pharmaceutical company that develops pharmaceutical drugs used to treat autoimmune and…
Khondrion Funding FAQs
What does Khondrion do?
We are a clinical-stage pharmaceutical company discovering and developing therapies targeting mitochondrial disease. Founded by Professor Jan Smeitink, a world-leader in mitochondrial medicine, we are advancing our proprietary science through a wholly-owned clinical and preclinical small molecule pipeline of potential medicines. Our priority is to rapidly develop our pipeline to deliver transformative medicines for patients living with mitochondrial disease. Our in-house scientists are driving innovative research projects and building a portfolio of promising compounds. We have active discovery programmes underway developing new therapies, biomarkers, diagnostic applications and new read-out technologies in the field of mitochondrial diseases. Our lead pipeline asset, KH176, is a potential first-in-class oral small molecule in phase IIb clinical development to treat a range of mitochondrial diseases. It has been granted Orphan Drug Designation for MELAS (mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes) spectrum disorders and Leigh disease in Europe and for all inherited mitochondrial respiratory chain disorders in the US. We work in collaboration with patient organisations internationally as well as a global clinical and academic network to accelerate the discovery and development of our potential medicines for patients with mitochondrial diseases
How much funding has Khondrion raised?
Khondrion has raised $5.7M across 2 rounds on record. The most recent is an undisclosed round of $5.7M announced in May 2025.
When did Khondrion last raise funding?
Khondrion's most recent funding round on record is an undisclosed round of $5.7M, announced in May 2025.
Who founded Khondrion?
FundedIQ lists Jan Smeitink (Founder) at Khondrion.
Where is Khondrion headquartered?
Khondrion is based in Nijmegen, Gelderland, Netherlands.
How many employees does Khondrion have?
Khondrion is in the 11-50 employee band.
How does Khondrion's funding compare to other Biotechnology startups?
Khondrion's latest round of $5.7M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Khondrion Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Khondrion is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.